Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) issued its quarterly earnings results on Tuesday. The specialty pharmaceutical company reported $1.72 EPS for the quarter, missing analysts’ consensus estimates of $1.85 by $0.13, Morningstar.com reports. The firm had revenue of $394.39 million for the quarter, compared to analysts’ expectations of $410.83 million. Jazz Pharmaceuticals PLC had a return on equity of 24.65% and a net margin of 26.28%. The business’s quarterly revenue was up 3.5% compared to the same quarter last year. During the same quarter last year, the firm earned $2.67 earnings per share. Jazz Pharmaceuticals PLC updated its FY17 guidance to $10.70-11.30 EPS.

Shares of Jazz Pharmaceuticals PLC (NASDAQ JAZZ) opened at 152.29 on Wednesday. The firm has a market capitalization of $9.14 billion, a PE ratio of 23.01 and a beta of 1.10. The company has a 50-day moving average of $155.76 and a 200 day moving average of $145.81. Jazz Pharmaceuticals PLC has a 12-month low of $95.80 and a 12-month high of $163.75.

A number of brokerages have recently commented on JAZZ. Sanford C. Bernstein set a $176.00 price target on shares of Jazz Pharmaceuticals PLC and gave the stock a “market perform” rating in a report on Monday, May 22nd. Leerink Swann set a $179.00 target price on shares of Jazz Pharmaceuticals PLC and gave the company a “buy” rating in a report on Thursday, April 27th. Vetr upgraded shares of Jazz Pharmaceuticals PLC from a “hold” rating to a “buy” rating and set a $151.11 target price for the company in a report on Tuesday, June 6th. Deutsche Bank AG restated a “buy” rating and issued a $176.00 target price on shares of Jazz Pharmaceuticals PLC in a report on Tuesday, July 4th. Finally, Piper Jaffray Companies set a $182.00 target price on shares of Jazz Pharmaceuticals PLC and gave the company a “buy” rating in a report on Friday, July 14th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and eighteen have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $183.41.

In other Jazz Pharmaceuticals PLC news, CEO Bruce C. Cozadd sold 30,000 shares of the stock in a transaction on Thursday, May 11th. The stock was sold at an average price of $153.47, for a total transaction of $4,604,100.00. Following the completion of the transaction, the chief executive officer now directly owns 296,418 shares in the company, valued at $45,491,270.46. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Michael Patrick Miller sold 200 shares of the stock in a transaction on Monday, May 15th. The stock was sold at an average price of $152.98, for a total value of $30,596.00. Following the transaction, the executive vice president now owns 22,623 shares of the company’s stock, valued at $3,460,866.54. The disclosure for this sale can be found here. Insiders have sold 40,600 shares of company stock valued at $6,245,820 over the last quarter. Corporate insiders own 4.30% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Monarch Partners Asset Management LLC bought a new position in Jazz Pharmaceuticals PLC during the first quarter valued at about $8,733,000. Canada Pension Plan Investment Board raised its position in Jazz Pharmaceuticals PLC by 587.5% in the first quarter. Canada Pension Plan Investment Board now owns 82,651 shares of the specialty pharmaceutical company’s stock valued at $11,995,000 after buying an additional 70,629 shares in the last quarter. Wells Fargo & Company MN raised its position in Jazz Pharmaceuticals PLC by 0.5% in the first quarter. Wells Fargo & Company MN now owns 503,759 shares of the specialty pharmaceutical company’s stock valued at $73,111,000 after buying an additional 2,529 shares in the last quarter. Sumitomo Mitsui Asset Management Company LTD raised its position in Jazz Pharmaceuticals PLC by 16.8% in the first quarter. Sumitomo Mitsui Asset Management Company LTD now owns 4,910 shares of the specialty pharmaceutical company’s stock valued at $712,000 after buying an additional 707 shares in the last quarter. Finally, Profund Advisors LLC raised its position in Jazz Pharmaceuticals PLC by 11.5% in the first quarter. Profund Advisors LLC now owns 2,877 shares of the specialty pharmaceutical company’s stock valued at $418,000 after buying an additional 296 shares in the last quarter. Hedge funds and other institutional investors own 86.43% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Jazz Pharmaceuticals PLC (JAZZ) Releases Earnings Results, Misses Expectations By $0.13 EPS” was published by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was illegally stolen and republished in violation of US & international copyright and trademark law. The correct version of this story can be read at https://www.americanbankingnews.com/2017/08/08/jazz-pharmaceuticals-plc-nasdaqjazz-announces-quarterly-earnings-results-misses-estimates-by-0-19-eps.html.

Jazz Pharmaceuticals PLC Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Earnings History for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.